BRPI0514509A - uso de composto n-aril diazaespiracìclicos no tratamento de dependência - Google Patents

uso de composto n-aril diazaespiracìclicos no tratamento de dependência

Info

Publication number
BRPI0514509A
BRPI0514509A BRPI0514509-0A BRPI0514509A BRPI0514509A BR PI0514509 A BRPI0514509 A BR PI0514509A BR PI0514509 A BRPI0514509 A BR PI0514509A BR PI0514509 A BRPI0514509 A BR PI0514509A
Authority
BR
Brazil
Prior art keywords
compounds
significant
effective
aryl
effects
Prior art date
Application number
BRPI0514509-0A
Other languages
English (en)
Inventor
Balwinder Singh Bhatti
Gregory J Gatto
Jozef Klucik
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of BRPI0514509A publication Critical patent/BRPI0514509A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

USO DE COMPOSTOS N-ARIL DIAZAESPIRACìCLICOS NO TRATAMENTO DE DEPENDêNCIA. A presente invenção refere-se a compostos, composições e métodos para tratamento de dependência de droga, dependência de nicotina e/ou obesidade. Os compostos são compostos N-arila diazaespirocílicos, análogos ligados por ponte de compostos N-heteroarila diazaespirocíclicos, ou pró-drogas ou metabolitos desses compostos. O grupo adia pode ser um anel heterocíclico (heteroarila) de cinco ou seis membros. Os compostos são eficazes na inibição da produção e/ou secreção de dopamina, e por conseguinte são eficazes na inibição do processo de recompensa fisiológica que está associado com a ingestão de nicotina e/ou drogas ilícitas. Os compostos e as composições podem ser administrados em quantidades eficazes para inibir a liberação de dopamina, sem resultar em efeitos colaterais adversos significativos (por exemplo, efeitos colaterais tais como aumentos significativos da pressão sangüínea e da freqüência cardíaca, efeitos negativos significativos sobre o trato gastrointestinal, e efeitos significativos sobre o músculo esquelético).
BRPI0514509-0A 2004-08-20 2005-08-18 uso de composto n-aril diazaespiracìclicos no tratamento de dependência BRPI0514509A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60347904P 2004-08-20 2004-08-20
PCT/US2005/029371 WO2006023630A2 (en) 2004-08-20 2005-08-18 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction

Publications (1)

Publication Number Publication Date
BRPI0514509A true BRPI0514509A (pt) 2008-06-10

Family

ID=35447974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514509-0A BRPI0514509A (pt) 2004-08-20 2005-08-18 uso de composto n-aril diazaespiracìclicos no tratamento de dependência

Country Status (16)

Country Link
US (1) US20060058328A1 (pt)
EP (1) EP1784184A2 (pt)
JP (1) JP2008510711A (pt)
KR (1) KR20070043008A (pt)
CN (1) CN101022801A (pt)
AU (1) AU2005277410B2 (pt)
BR (1) BRPI0514509A (pt)
CA (1) CA2575461A1 (pt)
IL (1) IL180929A0 (pt)
MX (1) MX2007002045A (pt)
NO (1) NO20070979L (pt)
NZ (1) NZ552792A (pt)
RU (1) RU2387647C9 (pt)
UA (1) UA92327C2 (pt)
WO (1) WO2006023630A2 (pt)
ZA (1) ZA200701193B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2008096746A1 (ja) * 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
AU2009205720A1 (en) * 2008-01-15 2009-07-23 Targacept, Inc. Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers
CN102070640A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种1,7-二氮杂螺[4,5]壬烷及其衍生物的合成方法
RU2582339C2 (ru) * 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
RU2635105C1 (ru) * 2016-07-15 2017-11-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" Способ получения 4-арил-2,7,9-триазаспиро[4.5]декан-6,8,10-трионов
EP3490992B1 (en) * 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US6022868A (en) * 1995-06-29 2000-02-08 Novo Nordisk Als Substituted azacyclic or azabicyclic compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5733912A (en) * 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
ES2162503T3 (es) * 1998-06-12 2001-12-16 Hoffmann La Roche Derivados diaza-espiro(3,5)nonanos.
WO2001030780A2 (en) * 1999-10-27 2001-05-03 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
HUP0300413A2 (hu) * 2000-04-10 2003-06-28 Pfizer Products Inc. Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
PT1519939E (pt) * 2002-07-05 2010-02-10 Targacept Inc Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização

Also Published As

Publication number Publication date
AU2005277410A1 (en) 2006-03-02
WO2006023630A2 (en) 2006-03-02
JP2008510711A (ja) 2008-04-10
UA92327C2 (ru) 2010-10-25
KR20070043008A (ko) 2007-04-24
CA2575461A1 (en) 2006-03-02
WO2006023630A3 (en) 2006-05-04
AU2005277410B2 (en) 2010-06-24
RU2387647C2 (ru) 2010-04-27
RU2007110020A (ru) 2008-09-27
NO20070979L (no) 2007-03-19
RU2387647C9 (ru) 2011-05-27
CN101022801A (zh) 2007-08-22
NZ552792A (en) 2009-12-24
MX2007002045A (es) 2007-03-29
US20060058328A1 (en) 2006-03-16
EP1784184A2 (en) 2007-05-16
ZA200701193B (en) 2009-09-30
IL180929A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
NO20070979L (no) Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet
DK1519939T5 (da) N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
BR0307291A (pt) Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano
NO20073719L (no) Kjemiske forbindelser
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
BR0315580A (pt) Derivados de metileno uréia
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
BRPI0514679A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
EA201001344A1 (ru) Азотсодержащие бициклические соединения, активные при состояниях хронической боли
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
BRPI0518094A (pt) uso de um derivado de piridotienopirimidina, composto de um derivado de piridotienopirimidina, composição farmacêutica, método de tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de cura pela inibição da fosfodiesterase 4 e produto de combinação
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
WO2009017383A3 (en) Sustained-release formulation comprising metformin acid salt
AR030410A1 (es) Derivados de 2-fenilpiran-4-ona, proceso para obtener dichos derivados, composiciones farmaceuticas que comprenden los derivados mencionados y el uso de los mismos en la manufactura de medicamentos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.